Market Overview
The India Veterinary Medicine Market was valued at approximately $918.47 million in 2025 and operates within the broader global veterinary medicine market, which reached $36.11 billion in 2024 and is projected to grow at a 7.1% CAGR through 2032. The Indian market encompasses a range of products including pharmaceuticals, biologics, vaccines, and parasiticides distributed through veterinary hospitals, pharmacies, and online channels. The sector benefits from India's position as one of the world's largest livestock and poultry producers, with animals categorized broadly into companion animals, livestock, and aquaculture species.
- •Pharmaceuticals accounted for 52.5% of global veterinary medicine revenue in 2025, with broad-spectrum anti-infectives and parasiticides being primary product categories
- •The global veterinary drugs sub-market was valued at $30.54 billion in 2025, projected to reach $53.05 billion by the early 2030s
- •Distribution occurs through veterinary hospitals, retail pharmacies, and increasingly through online veterinary pharmacies
Growth Drivers
India's growing livestock population, particularly cattle, buffalo, and poultry, creates sustained demand for veterinary medicines to maintain herd health and productivity. Rising pet humanization in urban centers has increased spending on companion animal healthcare, including vaccines, parasiticides, and specialty pharmaceuticals. Government initiatives supporting dairy development, animal husbandry, and disease control programs provide institutional demand and help expand access to veterinary care across rural and semi-urban regions.
- •Growing livestock population drives demand for vaccines, anti-infectives, and parasiticides to support meat, milk, and egg production
- •Rising pet ownership and human-animal bonding in urban India increase spending on companion animal pharmaceuticals and biologics
- •Government animal health programs and expanding veterinary infrastructure in rural areas support market penetration
Segmentation and Regional Analysis
The market is segmented by product into biologics (vaccines, antisera) and pharmaceuticals (antibiotics, parasiticides, anti-inflammatories), with pharmaceuticals maintaining the larger share. Animal-type segmentation covers companion animals (dogs, cats), livestock (cattle, buffalo, swine), and poultry, each with distinct treatment protocols and product demand patterns. Asia Pacific as a region represents a significant and fast-growing portion of the global market, with India positioned as a key emerging economy within it, benefiting from a large animal population base and improving veterinary healthcare access.
- •Products are classified as biologics versus pharmaceuticals, with route of administration (injectable, oral, topical) serving as a further categorization
- •Animal segments include companion animals, livestock, poultry, and aquaculture, each with tailored product requirements
- •Asia Pacific is a leading regional market, with India contributing through its vast livestock and poultry populations and expanding pet sector
Trends and Outlook
What are the recent trends and outlook?
The India Veterinary Medicine Market is expected to follow the broader global trajectory of steady compound annual growth, supported by rising animal health awareness, increasing disposable incomes, and ongoing improvements in veterinary infrastructure. Innovations in biologics, including next-generation vaccines and monoclonal antibody therapies, are expanding treatment options for both livestock and companion animals. The convergence of digital veterinary services and e-commerce for pet medications, combined with regulatory emphasis on antimicrobial stewardship and food safety, is shaping the competitive and operational landscape for market participants in the coming years.
- •Rising companion animal ownership and pet insurance penetration are expected to drive growth in specialty pet pharmaceuticals and biologics
- •Digitalization of veterinary services and online pharmacy platforms are expanding access to animal health products in urban and semi-urban markets
- •Regulatory emphasis on antimicrobial resistance, vaccine development, and food safety standards is influencing product development priorities and market access requirements
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.